Pharmaceutical evaluation of compounded furosemide capsules and excipient performance

Authors

  • Pabllo Adelino Estevam Barbosa Faculty of Pharmaceutical Sciences, Federal University of Amazonas, Manaus, AM, Brazil
  • Roberto B Rozário Faculty of Pharmaceutical Sciences, Federal University of Amazonas, Manaus, AM, Brazil
  • Tatiane P Souza Faculty of Pharmaceutical Sciences, Federal University of Amazonas, Manaus, AM, Brazil
  • Kátia S C R Santos Faculty of Pharmaceutical Sciences, Federal University of Amazonas, Manaus, AM, Brazil https://orcid.org/0000-0002-1054-2853

DOI:

https://doi.org/10.1590/s2175-97902022e20139

Keywords:

Drug compounding, Quality control, Capsules, Furosemide, Excipients

Abstract

Compounding pharmacies play an important role not only in compounding personalized formulations, but also preparing drugs at the same concentration and dosage as those from commercial manufacturers. The excipients used in compounding are generally standardized for many drugs, however they do not consider the intrinsic properties, such as the poor water solubility, of each substance. The excipient performance of commercially available compounded furosemide capsules in 7 compounding pharmacies from Manaus was evaluated and compared them to the performance of the reference medicinal product (Lasix® tablets) and 2 batches of capsules made in-house (T2 and T4) with a standardized excipient. All batches were subjected to tests for weight variation, assay, uniformity of dosage units, disintegration and dissolution profile. Of the 7 different compound formulas acquired in the compounding pharmacies, only 2 passed all tests. Most formulas passed the tests for weight determination, disintegration time and assay, however batches from 2 establishments failed in regards to the uniformity of the content and 5 batches failed the dissolution test. The reference medicinal product was approved in all tests, as were the T2 capsules made in-house with drug-excipient ratio 1:2. These results confirm the importance of the excipient composition, especially for poorly soluble drugs.

Downloads

Download data is not yet available.

References

Agência Nacional de Vigilância Sanitária - ANVISA (Brasil). Resolução RDC no67, de 08 de outubro de 2007. Dispõe sobre boas práticas de manipulação de preparações magistrais e oficinais para uso humano em farmácias. Diário Oficial da União 09 set 2007, p. 1-58.

Agência Nacional de Vigilância Sanitária. ANVISA (Brasil). Resolução RDC no 87, de 21 de novembro de 2008. Altera o regulamento técnico sobre boas práticas de manipulação em farmácias. Diário Oficial da União 24 nov 2008, p. 58-59.

Aglio TC. Determinação de peso médio, desintegração e teor de cápsulas de hidroclorotiazida manipuladas em farmácias magistrais de Juiz de Fora - MG. [Dissertação de Mestrado]. Juiz de Fora: Universidade Federal de Juiz de Fora, Faculdade de Farmácia; 2016.

Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12(3):413-420.

Aronson, H. Correction fator for dissolution profile calculations. J Pharm Sci. 1993;82(11):1190.

Associação Nacional de Farmacêuticos Magistrais. ANFARMAG. Perda de pó na manipulação: o que isso acarreta? 2015. [cited 2019 Oct 22]. Available from: Available from: http://www.anfarmag.com.br/ler-comunicado/perda-de-po-na- manipulacao:-o-que-isso-acarreta

» http://www.anfarmag.com.br/ler-comunicado/perda-de-po-na- manipulacao:-o-que-isso-acarreta

Associação Nacional de Farmacêuticos Magistrais. ANFARMAG. Panorama setorial anfarmag 2018. [cited 2019 Nov 27]. Available from: Available from: https://conteudo.anfarmag.org.br/panorama-setorial-2018

» https://conteudo.anfarmag.org.br/panorama-setorial-2018

Aulton ME, Taylor KMG. Aulton´s pharmaceutics: the design and manufacture of medicines. 4th ed. London: Elsevier; 2013.

Carr RL. Evaluating flow properties of solids. Chem Eng. 1965;72:163-168.

Castro AD, Vicente JA, Mourão SC, Bueno JHF, Evangelista RC, Gremião MPD. Efeito da concentração do amido de milho na liberação de paracetamol de comprimidos. Rev Bras Ciênc Farm. 2003;39(3):289-297.

Conceição CP, Vidal FVN, Santos EP, Ricci-Júnior E. Controle de qualidade de cápsulas manipuladas de diacereína. Rev Bras Farm. 2012;93(2):265-269.

Cruz ES. Controle de qualidade de cápsulas magistrais de hidroclorotiazida manipuladas no município de Lagarto - SE. [Trabalho de Conclusão de Curso]. Lagarto: Universidade Federal de Sergipe, Departamento de Farmácia; 2017.

Dave VS, Saoji SD, Raut NA, Haware RV. Excipient variability and its impact on dosage form functionality. J Pharm Sci . 2015;104(3):906-915.

Elder DP, Kuentz M, Holm R. Pharmaceutical expicients - quality, regulatory and biopharmaceutical considerations. Eur J Pharm Sci . 2016;87:88-99.

Evans RS, Lloyd JF, Stoddard GJ, Nebeker JR, Samore MH. Risk factors for adverse drug events: a 10-year analysis. Ann Pharmacother. 2005;39(7-8):1161-1168.

Farmacopeia Brasileira. 6. ed. Brasília: ANVISA; 2019, 2 v.

Food and Drug Administration. FDA. FDA´s human drug compounding progress report 2017. [cited 2019 Dec 19]. Available from: Available from: https://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug- compounding

» https://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug- compounding

Ferreira AO. Guia prático da farmácia magistral. 3. ed. São Paulo: Pharmabooks; 2008.

García-Arieta A. Interactions between active pharmaceuticals ingredients and excipients affecting bioavailability: impact on bioequivalence. Eur J Pharm Sci . 2014;65:89-97.

Gudeman J, Jozwiakowski M, Chollet J, Randell M. Potential risks of pharmacy compounding. Drugs R D. 2013;13(1):1-8.

Guharoy R, Noviasky J, Haydar Z, Fakih MG, Hartman C. Compounding pharmacy conundrum: “we cannot live without them but we cannot live with them” according to the present paradigm. Chest. 2013;143(3):896-900.

Gullapalli RP, Mazzitelli CL. Gelatin and non-gelatin capsule dosage forms. J Pharm Sci . 2017;106(6):1453-1465.

Hoag SW. Capsule dosage form: formulation and manufacturing considerations. In: Qiu Y, Chen Y, Zhang GGZ, Yu L, Mantri RV. Solid oral dosage forms. 2nd ed. London: Elsevier ; 2017. p. 723-747.

Jain GK, Ahmad FJ, Khar RK. Micromeritics. In: Theory and practice of physical pharmacy. Haryana: Elsevier; 2012. p. 23-64.

Joshi AA, Duriez X. Added functionality excipients: an answer to challenging formulations. Pharm Tech. 2004;22:12-19.

Lamolha MA, Cunha AG, Castro IC, Neri IM, Ferreira MC. Excipientes pré-formulados para a manipulação de cápsulas: uma realidade magistral. Rev Anfarmag. 2014;100(Jan/Feb/ Mar):48-52.

Machado TC, Silveira RL, Laporta LV, Santos MR. Influência de excipientes na manipulação de cápsulas de furosemida. Discip Sci Sér Saúde. 2012;13(1):27-39.

Markman BLO, Rosa PCP, Koschtschak MRW. Avaliação da qualidade de cápsulas de sinvastatina de farmácias magistrais. Rev Saúde Públ. 2010;44(6):1055-1062.

Marques-Marinho FD, Zanon JCC, Sakurai E, Reis IA, Lima AA, Vianna-Soares CD. Quality evaluation of simvastatin compounded capsules. Braz J Pharm Sci . 2011;47(3):495-502.

Narang AS, Boddu SHS. Excipient applications in formulation design and drug delivery. In: Narang AS, Boddu SHS, editors. Excipient applications in formulation design and drug delivery. London: Springer; 2015, p. 1-10.

Oliveira MA, Yoshida MI, Silva DCGM. Quality evaluation of pharmaceutical formulations containing hydrochlorothiazide. Molecules. 2014;19(10):16824-16836.

Pifferi G, Santoro P, Pedrani M. Quality and functionality of excipients. Farmaco. 1999;54(1-2):1-14.

Silva TFF, Torres MPR, Raiser AL, Ribeiro EB, Andrighetti CR, Marques MZ, Vasconcelos LG, Valladão DMS. Quality control of ranitidine hydrochloride compounded capsules. Sci Eletronic Arch. 2018;11(5):154-161.

Thompson JE, Davidow LW. A practical guide to contemporary pharmacy practice. 3rd. ed. Philadelphia: Lippincott Williams & Wilkins; 2009.

Ullmann P. Practice update: excipient selection for compounded pharmaceutical capsules: they´re only fillers, right? Aust J Pharm. 2017;98(1164):78-83.

Villanova JCO, Sá VR. Excipientes: guia prático para padronização: formas farmacêuticas orais sólidas e líquidas. São Paulo: Pharmabooks ; 2010.

Yalkowsky SH, Bolton S. Particle size and content uniformity. Pharm Res . 1990;7(9):962-966.

Zarmpi P, Flanagan T, Meehan E, Mann J, Fotaki N. Biopharmaceutical aspects and implications of excipient variability in drug product performance. Eur J Pharm Biopharm. 2017;111:1-15.

Zvonar A, Berginc K, Kristi A, Gasperlin M. Microencapsulation of self-microemulsifying system: improving solubility and permeability of furosemide. Int J Pharm. 2010;388(1):151-158.

Downloads

Published

2022-12-23

Issue

Section

Original Article

How to Cite

Pharmaceutical evaluation of compounded furosemide capsules and excipient performance. (2022). Brazilian Journal of Pharmaceutical Sciences, 58. https://doi.org/10.1590/s2175-97902022e20139